08:00 Thu 30 Apr 2020
BATM Advanced Comm - COVID-19 Update
LEI: 213800FLQUB9J289RU66
("BATM" or "the Group")
COVID-19 Update
BATM (LSE: BVC; TASE: BVC), a leading provider of real-time technologies for networking solutions and medical laboratory systems, provides the following update regarding COVID-19.
The effectiveness of the Group's response has been enabled by the significant investments it has made in advancing its Bio-Medical division in recent years, which is now able to quickly provide solutions that include diagnostic kits for any new pathogen that appears and devices like diagnostic instruments, ventilators, pathogenic waste disposal and more. The Group also responded rapidly to prepare its Bio-Medical division when it was first alerted to the potential outbreak.
Consequently, the Group was able to launch a new diagnostics kit to detect COVID-19 that underwent clinical verification and evaluation by leading universities and hospitals in February and received certification in
In addition, as announced last week, the Group received an order of
The Group's primary facilities in the Bio-Medical division, in
In the Networking & Cyber division, the Group's facilities have remained open in both
As a result of the above, the Group expects the Bio-Medical division to perform well and the Networking & Cyber division to experience a temporary slowdown. Given the uncertainty surrounding the length and economic severity of the crisis, it is too early to estimate the financial impact on BATM for full year 2020.
BATM continues to work hard to ensure its employees are fully supported in remaining safe, well and able to work. Today, BATM is well positioned in large markets showing long-term growth potential and with a set of technologies, services and solutions to meet its customers' evolving needs. As a result, the Board believes that, with the actions taken to date in response to the pandemic along with the further work to be undertaken to achieve the Group's strategic objectives in 2020, BATM will continue to deliver shareholder value.
Enquiries:
|
|
Dr |
+972 9866 2525 |
|
|
|
|
|
|
Shore Capital |
|
|
+44 20 7408 4050 |
|
|
|
|
|
|
Harry Chathli, |
+44 20 7618 9100 |
This information is provided by RNS, the news service of the
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of...
FOR OUR FULL DISCLAIMER CLICK HERE